Drug Profile

RC 010

Alternative Names: RC-010

Latest Information Update: 30 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nanjing Reju Therapeutics
Class Antifibrotics; Esters; Isoquinolines; Small molecules
Mechanism of Action Bcl-X protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Idiopathic pulmonary fibrosis
New Molecular Entity Yes

Highest Development Phases

Preclinical Idiopathic pulmonary fibrosis

Most Recent Events

22 Apr 2026 Preclinical trials in Idiopathic pulmonary fibrosis in China (Inhalation), prior to April 2026
14 Apr 2026 Nanjing Reju Therapeutics plans a phase Ia trial for Idiopathic pulmonary fibrosis (In volunteers) in China (Inhalation, Powder) (NCT07528703) (CTR20261112)
15 Jan 2026 RC 010 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com